{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-028113","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.208641+00:00","generated_at":"2026-06-27T03:31:05.884877+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagonist reports Q4 2021 net loss $36.9M; cash $326.9M; rusfertide Phase 3 to start Q1 2022","bullets":["Net loss Q4 2021 $36.9M ($0.77/share) vs $18.9M ($0.48/share) in Q4 2020; full year loss $125.6M ($2.71/share) vs $66.2M ($1.92/share).","Cash, equivalents and marketable securities $326.9M as of Dec 31, 2021; expected to fund operations through 2024.","Phase 3 VERIFY study of rusfertide in polycythemia vera to initiate Q1 2022; topline PN-943 Phase 2 UC data expected Q2 2022.","Phase 2b FRONTIER 1 study of PN-235 in plaque psoriasis initiated; $25M milestone due upon dosing third patient.","R&D expenses Q4 2021 $38.4M (vs $19.5M); full year $126.0M (vs $74.5M) on advancing pipeline and employee costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-028113","json":"https://secwatch.observer/filing/0001104659-22-028113.json","markdown":"https://secwatch.observer/filing/0001104659-22-028113.md","text":"https://secwatch.observer/filing/0001104659-22-028113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922028113/0001104659-22-028113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922028113/tm227855d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:31:05.884877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}